Answers are grounded in this paper and cite their sources.
PURPOSE Treatment options for patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) are limited. Limited preclinical and clinical data suggested benefit of pemetrexed in patients with R/M SGC but, to our knowledge, no prospective data exist. We conducted a phase II trial of the combination of pemetrexed and pembrolizumab in patients with R/M SGC; results from the nonadenoid cystic carcinoma (ACC) cohort are reported. PATIENTS AND METHODS MC200708 is a phase II study of pemetrexed and pembrolizumab in patients with R/M SGC (ClinicalTrials.gov identifier: NCT04895735 ). Simon's two-stage design was used. Any number of prior therapies were allowed. Primary end point was overall response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), and toxicity. All patients received pemetrexed 500 mg/m 2 IV once every 3 weeks and pembrolizumab 200 mg IV once every 3 weeks until progression or treatment intolerance. RESULTS Twenty-five patients were enrolled; 24 were eligible and treated. Nine of 24 patients had a confirmed response for ORR of 37.5% (95% CI, 18.8 to 59.4). The ORR for patients with salivary duct carcinoma (SDC) was 63.6%. Median duration of response was 15.3 months (95% CI, 12.4 to not reached). Median OS was 20.0 months (95% CI, 17.1 to not reached) and median PFS was 6.2 months (95% CI, 2.1 to 17.3). One-year OS and PFS rates were 71.9% (95% CI, 55.0 to 94.0) and 36.1% (95% CI, 21.0 to 62.2), respectively. Seven patients (29.2%) had ≥1 grade 3 to 4 toxicity, the majority hematologic. The five patients with grade 3 to 4 nonhematologic toxicity had grade 3 fatigue, rash, heart failure, hematuria, mastoiditis, and hypokalemia. CONCLUSION Pemetrexed and pembrolizumab has promising and durable activity in patients with R/M SGC, with notable responses in patients with SDC.
No takes yet. Share an insight, caveat, or question.
Price et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: